Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A Natural Clinical Trial

Abbas et al., Int. J. Clin. Pract., doi:10.1111/ijcp.13856
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
Prospective study of 161 hospitalized patients in Iraq showing HCQ+AZ appears to help recovery. Most mortality was in patients that were already in critical condition on admission and died before treatment could be effective.
Abbas et al., 24 Nov 2020, prospective, Iraq, peer-reviewed, 8 authors.
This PaperHCQAll
Assessment of COVID‐19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial
Hassan M Abbas, Ali Azeez Al‐jumaili, Kawthar F Nassir, Muhammed Waheeb Al‐obaidy, Adnan Mohammed Al Jubouri, Basim Dhawi Dakhil, Mohammed Mahir Abdulelah, Qutaiba Ahmed Al Khames
International Journal of Clinical Practice, doi:10.1111/ijcp.13856
The goal of this study was to assess the clinical effectiveness and safety profile of the COVID-19 treatment protocol (containing both hydroxychloroquine (HCQ) and azithromycin) in an Iraqi specialised hospital. Methods : This prospective study used a pre-and post-intervention design without a comparison group. The intervention was routine Ministry of Health (MOH) approved the management of COVID-19 for all patients. The study was conducted in a public healthcare setting in Baghdad, Iraq from March 1st to May 25, 2020. The study outcome measures included the changes in clinical and biochemical parameters during the hospitalisation period. Paired t-test and Chi-square test were used to compare the measures of vital signs, lab tests and symptoms before and after treatment. Results: The study included 161 patients who were admitted with positive RT-PCR and clinical symptoms of COVID-19. In terms of severity, 53 (32.9%) patients had amild condition, 47 (29.2%) had moderate condition, 35 (21.7%) had severe condition and 26 (16.1%) had critical condition. Most patients (84.5%) recovered and were discharged without symptoms after testing negative with RT-PCR, while 11 (6.8%) patients died during the study period. The signs and symptoms of COVID-19 were reduced significantly in response to a therapy regimen containing HCQ and azithromycin. The most common reported side effects were stomach pain, hypoglycemia, dizziness, itching, skin rash, QT prolongation, arrhythmia, and conjunctivitis. Conclusions: This natural trial showed that the COVID-19 regimen containing both HCQ and azithromycin can be helpful to promote the recovery of most patients and reduced their signs and symptoms significantly. It also shows some manageable side effects mostly those related to heart rhythm. In the absence of FDA-approved medications to treat COVID-19, the repurposing of HCQ and azithromycin to control the disease signs and symptoms can be useful. | INTRODUC TI ON Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus that was first recognised in Wuhan, China, in December 2019. 1 Genetic sequencing of the virus suggests that it is a beta-corona virus closely linked to the SARS virus. 2 While most people with COVID-19 develop the only mild or uncomplicated illness, approximately 14% develop a severe disease that requires hospitalisation and oxygen support, and 5% require admission to an intensive care unit. 3 In severe cases, COVID-19 can be
and symptoms is potentially useful. The study showed that using this therapy combination (HCQ and azithromycin) is promising and can fill the gap until more effective treatments are found. Future randomised controlled trial can give more definite answers about the effectiveness and safety of such therapy protocol. ACK N OWLED G EM ENTS The authors would like to thank Dr Jawad Rasheed, Dr Ali AL-Garrawy and all the physicians and healthcare provider in Al-Shifaa Centre for Corona pandemic at Medical City, Baghdad who helped the research team conduct the study. If they had not bravely risked their lives to treat the COVID-19 cases, there would not be such a high recovery rate amongst patients. CO N FLI C T O F I NTE R E S T No conflict of interest to declare and the study received no fund.
References
Allawi, Abbas, Rasheed, The first 40-days experience and clinical outcomes in the management of coronavirus covid-19 crisis. Single center preliminary study, J Fac Med Baghdad
Center, WHO Causality assessment, Good Pharmacovigil Pract Guid
Cucinotta, Vanelli, WHO declares COVID-19 a pandemic, Acta Biomed, doi:10.23750/abm.v91i1.9397
D'acquarica, Agranat, Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19, Drug Discov Today, doi:10.1016/j.drudis.2020.04.021
Damle, Vourvahis, Wang, Leaney, Corrigan, Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19, Clin Pharmacol Ther, doi:10.1002/cpt.1857
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Gbinigie, Frie, Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review, BJGP Open, doi:10.3399/bjgpopen20X101069
Guo, Cao, Hong, The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-A n update on the status, Mil Med Res, doi:10.1186/s40779-020-00240-0
Gérard, Romani, Fresse, Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers, Therapies, doi:10.1016/j.therap.2020.05.002
Haładyj, Sikora, Felis-Giemza, Olesinska, Antimalarialsare they effective and safe in rheumatic diseases?, Reumatologia, doi:10.5114/reum.2018.76904
Ikeda, Rokutanda, The side effect and the retention rate of hydroxychloroquine in Japan. St Luke's, Int Hosp Tokyo
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105924
Maa, Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases, Pharmacol Res Perspect, doi:10.1002/prp2.293
Mackenzie, Smith, COVID-19: A novel zoonotic disease caused by a coronavirus from China: What we know and what we don't, Microbiol Aust, doi:10.1071/MA20013
Mehra, Desai, Ruschitzka, Patel, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet, doi:10.1016/S0140-6736(20)31180-6
Meyerowitz, Vannier, Friesen, Rethinking the role of hydroxychloroquine in the treatment of COVID-19, FASEB J, doi:10.1096/fj.202000919
Mikhael, Aa, Can developing countries face novel coronavirus outbreak alone? The Iraqi situation, Public Heal Pract, doi:10.1016/j.puhip.2020.100004
O'laughlin, Mehta, Wong, Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine, Case Reports Cardiol, doi:10.1155/2016/4626279
Ramireddy, Chugh, Reinier, Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring, medRxiv, doi:10.1016/j.solener.2019.02.027
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A Review, JAMA-J Am Med Assoc, doi:10.1001/jama.2020.6019
Ss, COVID-19 Dashboard
Tamblyn, Clinical management of patients with moderate to severe COVID-19 -Interim Guidance
Tétu, Hamelin, Lebrun-Vignes, Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: A retrospective survey of 102 patients, Ann Dermatol Venereol, doi:10.1016/j.annder.2018.03.168
Ullah, Araf, Sarkar, Moin, Reshad, Pathogenesis, Diagnosis and Possible Therapeutic Options for COVID-19, doi:10.20944/PREPRINTS202004.0372.V1
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
{ 'indexed': {'date-parts': [[2024, 2, 23]], 'date-time': '2024-02-23T12:33:06Z', 'timestamp': 1708691586404}, 'reference-count': 28, 'publisher': 'Hindawi Limited', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2020, 12, 5]], 'date-time': '2020-12-05T00:00:00Z', 'timestamp': 1607126400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}, { 'start': { 'date-parts': [[2020, 12, 5]], 'date-time': '2020-12-05T00:00:00Z', 'timestamp': 1607126400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'http://doi.wiley.com/10.1002/tdm_license_1.1'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 4]]}, 'DOI': '10.1111/ijcp.13856', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 11, 25]], 'date-time': '2020-11-25T05:16:27Z', 'timestamp': 1606281387000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 14, 'title': 'Assessment of COVID‐19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural ' 'clinical trial', 'prefix': '10.1155', 'volume': '75', 'author': [ { 'given': 'Hassan M.', 'family': 'Abbas', 'sequence': 'first', 'affiliation': [{'name': 'Headquarter Ministry of Health Baghdad Iraq'}]}, { 'ORCID': 'http://orcid.org/0000-0003-4691-0280', 'authenticated-orcid': False, 'given': 'Ali Azeez', 'family': 'Al‐Jumaili', 'sequence': 'additional', 'affiliation': [ {'name': 'College of Pharmacy University of Iowa Iowa City IA USA'}, { 'name': 'Clinical Pharmacy Department University of Baghdad College of ' 'Pharmacy Baghdad Iraq'}]}, { 'ORCID': 'http://orcid.org/0000-0002-4266-3115', 'authenticated-orcid': False, 'given': 'Kawthar F.', 'family': 'Nassir', 'sequence': 'additional', 'affiliation': [ { 'name': 'Therapeutic Drug Monitoring Center Baghdad Teaching ' 'HospitalMedical City Complex Baghdad Iraq'}]}, { 'given': 'Muhammed Waheeb', 'family': 'Al‐Obaidy', 'sequence': 'additional', 'affiliation': [{'name': 'University of Baghdad College of Medicine Baghdad Iraq'}]}, { 'given': 'Adnan Mohammed', 'family': 'Al Jubouri', 'sequence': 'additional', 'affiliation': [ {'name': 'University of Baghdad College of Medicine Baghdad Iraq'}, { 'name': 'Baghdad Teaching HospitalMedical City Teaching Complex Baghdad ' 'Iraq'}]}, { 'given': 'Basim Dhawi', 'family': 'Dakhil', 'sequence': 'additional', 'affiliation': [ { 'name': 'Critical Care Unit Bagdad Teaching Hospital Medical City Complex ' 'Internal Medicine Department in Al‐Shifa center for the ' 'treatment of COVID‐19 Baghdad Iraq'}]}, { 'given': 'Mohammed Mahir', 'family': 'Abdulelah', 'sequence': 'additional', 'affiliation': [ { 'name': 'Intensive Care Unit Bagdad Teaching HospitalMedical City Complex ' 'Baghdad Iraq'}]}, { 'given': 'Qutaiba Ahmed', 'family': 'Al Khames', 'sequence': 'additional', 'affiliation': [{'name': 'Faculty of Pharmacy Philadelphia University Amman Jordan'}]}], 'member': '98', 'published-online': {'date-parts': [[2020, 12, 5]]}, 'reference': [ {'key': 'e_1_2_10_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s40779-020-00240-0'}, {'key': 'e_1_2_10_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1071/MA20013'}, { 'key': 'e_1_2_10_4_1', 'first-page': '1', 'article-title': 'Clinical management of patients with moderate to severe COVID‐19 ‐ ' 'Interim Guidance', 'author': 'Tamblyn S', 'year': '2020', 'journal-title': 'Public Heal Agency Canada'}, { 'key': 'e_1_2_10_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30566-3'}, { 'issue': '1', 'key': 'e_1_2_10_6_1', 'first-page': '157', 'article-title': 'WHO declares COVID‐19 a pandemic', 'volume': '91', 'author': 'Cucinotta D', 'year': '2020', 'journal-title': 'Acta Biomed'}, { 'key': 'e_1_2_10_7_1', 'unstructured': 'And C for SS Engineering (CSSE) JHU (JHU). COVID‐19 ' 'Dashboard.https://coronavirus.jhu.edu/map.html. Published 2020. Accessed ' 'June 24 2020.'}, { 'key': 'e_1_2_10_8_1', 'doi-asserted-by': 'crossref', 'unstructured': 'UllahMA ArafY SarkarB MoinAT ReshadRAI.Pathogenesis Diagnosis and ' 'Possible Therapeutic Options for ' 'COVID‐19.2020;https://doi.org/10.20944/PREPRINTS202004.0372.V1', 'DOI': '10.20944/preprints202004.0372.v1'}, { 'key': 'e_1_2_10_9_1', 'unstructured': 'FDA.Coronavirus Treatment Acceleration Program ' '(CTAP).https://www.FDA.gov/drugs/coronavirus‐covid‐19‐drugs/coronavirus‐treatment‐acceleration‐program‐ctap.2020. ' 'Accessed June 3 2020.'}, { 'key': 'e_1_2_10_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.drudis.2020.04.021'}, {'key': 'e_1_2_10_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3399/bjgpopen20X101069'}, { 'key': 'e_1_2_10_12_1', 'first-page': '1', 'article-title': 'Clinical pharmacology perspectives on the antiviral activity of ' 'azithromycin and use in COVID‐19', 'author': 'Damle B', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'issue': '3', 'key': 'e_1_2_10_13_1', 'article-title': 'The first 40‐days experience and clinical outcomes in the management of ' 'coronavirus covid‐19 crisis. Single center preliminary study', 'volume': '61', 'author': 'Allawi JS', 'year': '2019', 'journal-title': 'J Fac Med Baghdad'}, { 'issue': '3', 'key': 'e_1_2_10_14_1', 'first-page': '39', 'article-title': 'WHO Causality assessment', 'author': 'Center WHO‐TUM', 'year': '2009', 'journal-title': 'Good Pharmacovigil Pract Guid'}, { 'key': 'e_1_2_10_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijantimicag.2020.105924'}, {'key': 'e_1_2_10_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.5114/reum.2018.76904'}, { 'key': 'e_1_2_10_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.puhip.2020.100004'}, { 'key': 'e_1_2_10_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijantimicag.2020.105949'}, {'key': 'e_1_2_10_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/prp2.293'}, { 'issue': '18', 'key': 'e_1_2_10_20_1', 'article-title': 'Pharmacologic treatments for coronavirus disease 2019 (COVID‐19): A ' 'Review', 'volume': '323', 'author': 'Sanders JM', 'year': '2020', 'journal-title': 'JAMA‐J Am Med Assoc'}, {'key': 'e_1_2_10_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1096/fj.202000919'}, { 'issue': '1', 'key': 'e_1_2_10_22_1', 'first-page': 'A1', 'article-title': 'The side effect and the retention rate of hydroxychloroquine in Japan', 'volume': '5', 'author': 'Ikeda Y', 'year': '2018', 'journal-title': 'St Luke’s Int Hosp Tokyo, Japan'}, { 'key': 'e_1_2_10_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.annder.2018.03.168'}, {'key': 'e_1_2_10_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1155/2016/4626279'}, { 'key': 'e_1_2_10_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.therap.2020.05.002'}, { 'issue': '1', 'key': 'e_1_2_10_26_1', 'first-page': '1', 'article-title': 'Experience with Hydroxychloroquine and Azithromycin in the COVID‐19 ' 'Pandemic: Implications for QT Interval Monitoring', 'volume': '21', 'author': 'Ramireddy A', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': 'e_1_2_10_27_1', 'unstructured': 'COVID‐19 Prevention and Control 2020 Chinese Centre for Disease Control ' 'and Prevention'}, { 'key': 'e_1_2_10_28_1', 'article-title': 'Hydroxychloroquine or chloroquine with or without a macrolide for ' 'treatment of COVID‐19: a multinational registry analysis', 'author': 'Mehra MR', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': 'e_1_2_10_29_1', 'unstructured': 'Coronavirus ( COVID‐19 ) Update\u202f: FDA Revokes Emergency Use ' 'Authorization for Chloroquine and Hydroxychloroquine ' 'Inquiries.2020;1‐3.'}], 'container-title': 'International Journal of Clinical Practice', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.13856', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1111/ijcp.13856', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.13856', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 1, 28]], 'date-time': '2022-01-28T06:07:03Z', 'timestamp': 1643350023000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1111/ijcp.13856'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 12, 5]]}, 'references-count': 28, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2021, 4]]}}, 'alternative-id': ['10.1111/ijcp.13856'], 'URL': 'http://dx.doi.org/10.1111/ijcp.13856', 'relation': {}, 'ISSN': ['1368-5031', '1742-1241'], 'subject': [], 'container-title-short': 'Int J Clin Pract', 'published': {'date-parts': [[2020, 12, 5]]}, 'assertion': [ { 'value': '2020-06-25', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-11-18', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-12-05', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit